Cite
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
MLA
Schey, Stephen A., et al. “The Addition of Cyclophosphamide to Lenalidomide and Dexamethasone in Multiply Relapsed/Refractory Myeloma Patients; a Phase I/II Study.” British Journal of Haematology, vol. 150, no. 3, Aug. 2010, pp. 326–33. EBSCOhost, https://doi.org/10.1111/j.1365-2141.2010.08250.x.
APA
Schey, S. A., Morgan, G. J., Ramasamy, K., Hazel, B., Ladon, D., Corderoy, S., Jenner, M., Phekoo, K., Boyd, K., & Davies, F. E. (2010). The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology, 150(3), 326–333. https://doi.org/10.1111/j.1365-2141.2010.08250.x
Chicago
Schey, Stephen A., Gareth J. Morgan, Karthik Ramasamy, Beth Hazel, Dariusz Ladon, Sophie Corderoy, Matthew Jenner, Karen Phekoo, Kevin Boyd, and Faith E. Davies. 2010. “The Addition of Cyclophosphamide to Lenalidomide and Dexamethasone in Multiply Relapsed/Refractory Myeloma Patients; a Phase I/II Study.” British Journal of Haematology 150 (3): 326–33. doi:10.1111/j.1365-2141.2010.08250.x.